[{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. and Dr Falk Pharma GmbH Announce the Start of The Phase II Study of Naronapride in Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Naronapride
ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4 receptor agonist and D2 receptor antagonist. It is being evaluated for the treatment of Gastroparesis.
ATI-7505 (naronapride) is an orally bioavailable, small organic molecule. It was designed to be a potent and selective serotonin 5-HT4 receptor agonist and D2 antagonist. Its IND application has been cleared by USFDA for the treatment of PPI-Non-Responsive Symptomatic GERD.
ATI-7505 (naronapride) is a 5-HT4 agonist, small molecule drug candidate, which is currently being evaluated for the treatment of proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease.
ATI-7505 (naronapride) is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, is being developed for GI motility in cystic fibrosis.
Naronapride possess both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties. It is currently being investigaetd for chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).
The collaboration with Dr. Falk Pharma will serve as a catalyst to Renexxion advancing Naronapride, a drug candidate which possesses combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties to patients with GI motility disorders.